# Applied XLabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/applied-xlabs

- Industry: Information Services
- Headquarters: Brooklyn, US
- Website: www.appliedxl.com
- Total disclosed funding: $5M
- Latest round: Seed (Mar 10, 2022)
- Investors on record: 9

## About

Applied XLabs, Inc. is a US-based company specializing in developing a Clinical Intelligence Platform that utilizes artificial intelligence to deliver timely insights for the biopharmaceutical industry.Founded in 2020 and headquartered in Brooklyn, US, Applied XLabs, Inc. focuses on providing advanced analytics for clinical trials. The company has completed 3 deals, with the most recent occurring on February 23, 2023, when it raised USD 1 mn in Seed funding. The current valuation of the company stands at USD 15.964 mn. The firm was co-founded by Erin Riglin and Francesco Marconi, with Marconi serving as CEO.Applied XLabs specializes in a Clinical Intelligence Platform that leverages artificial intelligence to deliver real-time insights across the biopharmaceutical sector. The platform provides critical information before it becomes news, focusing on clinical trial risk management, regulatory monitoring, and risk exposure analysis. Key offerings include tools for early detection of subtle deviations in clinical trials, automated drug program identification, and contextual analysis of trial outcomes. This suite of services empowers clients, including biotech companies and contract research organizations (CROs), to navigate the complexities of clinical trials and regulatory landscapes effectively, serving a global client base primarily in North America and Europe.AppliedXL generates revenue through a subscription-based model, offering clients access to its comprehensive suite of tools and insights tailored for the biopharmaceutical industry. Clients engage in partnerships for ongoing access to the Clinical Intelligence Platform, which features real-time trial briefings and automated identification of risk factors. Revenue streams also include enterprise agreements with larger biotech firms that require customized solutions. The pricing structure accommodates various client sizes and needs, facilitating seamless integration of AppliedXL's innovative analytics into existing workflows and research methodologies.In February 2023, Applied XLabs, Inc. raised USD 1 mn in Seed funding, which will be allocated towards developing new product offerings and enhancing the Clinical Intelligence Platform. The company plans to expand into additional markets in Europe and North America by the end of 2024, aiming to meet the rising demand for real-time biopharma insights.

## Funding rounds

- Seed, Mar 10, 2022, $3.5M — Correlation Ventures, Boston Globe Media Partners, LLC, Hearst Ventures, Tuesday Capital, Alumni Ventures Group, DataPower Ventures, Boston Globe Life Sciences Media, LLC
- Seed, Apr 21, 2021, $1.5M — Correlation Ventures, Team Europe, Tuesday Capital, frogVentures

## Investors

- Correlation Ventures (https://capitalatlas.ai/funds/correlation-ventures) — Seed
- Team Europe (https://capitalatlas.ai/funds/team-europe) — Seed
- Tuesday Capital (https://capitalatlas.ai/funds/tuesday-capital) — Seed
- frogVentures — Seed
- Boston Globe Media Partners, LLC — Seed
- Hearst Ventures (https://capitalatlas.ai/funds/hearst-ventures) — Seed
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Seed
- DataPower Ventures — Seed
- Boston Globe Life Sciences Media, LLC — Seed